Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04447469
Recruitment Status : Completed
First Posted : June 25, 2020
Last Update Posted : March 17, 2022
Information provided by (Responsible Party):
Kiniksa Pharmaceuticals, Ltd.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : November 12, 2021
Actual Study Completion Date : January 14, 2022